$2bn AbbVie Deal Puts I-Mab On Global Immuno-Oncology Map
Safety Of CD47 Asset A Major Attraction?
In another clear signal that China's innovative drug R&D is coming of age, most global rights to I-Mab's promising early-stage CD47 antibody have been picked up by AbbVie in a deal valued at close to $2bn.
